Therapeutic strategies for hepatitis B virus infection: towards a cure

• Published in: Nature reviews. Drug discovery Vol. 18; no. 11; pp. 827 - 844
• Main Authors: Fanning, Gregory C., Zoulim, Fabien, Hou, Jinlin, Bertoletti, Antonio
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2019; Nature Publishing Group
• Subjects: 631/154; 631/326/596/1550; 692/699/255/234/2513; Animals; Antigens; Antiviral agents; Antiviral Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cancer; Cancer Research; Control; Drug development; Drug therapy; Drug Therapy, Combination; Growth; Hepatitis; Hepatitis B; Hepatitis B - drug therapy; Hepatitis B - virology; Hepatitis B virus; Hepatitis B virus - drug effects; Humans; Infections; Life Sciences; Liver diseases; Medicinal Chemistry; Molecular Medicine; Pharmacology/Toxicology; Product development; Review Article; China
• ISSN: 1474-1776; 1474-1784; 1474-1784
• DOI: 10.1038/s41573-019-0037-0

Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide drugs are available and reduce both new infection rates and the development of liver disease in HBV-positive persons who adhere to long-term suppressive treatment. Although there is still considerable value in optimizing access to virus-suppressing regimens, the scientific and medical communities have embarked on a concerted journey to identify new antiviral drugs and immune interventions aimed at curing infection. The mechanisms and drug targets being explored are diverse; however, the field universally recognizes the importance of addressing the persistence of episomal covalently closed circular DNA, the existence of integrated HBV DNA in the host genome and the large antigen load, particularly of hepatitis B surface antigen. Another major challenge is to reinvigorate the exhausted immune response within the liver microenvironment. Ultimately, combinations of new drugs will be required to cure infection. Here we critically review the recent literature that describes the rationale for curative therapies and the resulting compounds that are being tested in clinical trials for hepatitis B. Drug development for treatment of hepatitis B virus infection has trailed behind that for infection with the related hepatitis C virus, but encouraging progress has been made in recent years. Fanning and colleagues review advances in hepatitis B therapies and challenges for their development, including antiviral and immune-boosting strategies that could be part of combination strategies to achieve functional cure.